HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tariff Hikes On Chinese Imports Still In Play As US Plans December Increase

Executive Summary

Trump administration negotiations with China representatives led to US suspending tariff increase to 25% on product categories announced set to begin 15 October. But 15% tariff added in September on about $112bn worth of Chinese goods remains and US still plans in December to impose separate 10% tariff hike on $160bn in other products.

You may also be interested in...



Coronavirus Disruption Likely In Supply Chain, Stockpiling Spikes Consumer Health Sales

Hand sanitizer, vitamin, energy drink, first-aid kis and medical face mask sales soar globally as consumers fearing spread of the coronavirus stockpile food and other essentials, a Nielsen report shows. FDA says outbreak could lead to interruptions in drug and medical device supplies; agency has not addressed consumer health supplies specifically, and industry is increasingly concerned with availability.

Essential Oils Off EU Imports Tariff List In Trade War Win For Fragrance Creators

Essential oils no longer on list of products slated for EU tariff increases effective 18 October, a win for US fragrance industry facing uncertainty in tumultuous global trade climate. Fragrancy industry, like dietary supplement manufacturers, still face higher tariffs on imports from China as next round of hikes is scheduled to start 15 October.

Full Plate Of Dietary Ingredients In Latest US Tariff Hikes On Chinese Imports

Consumer health industry groups plan to comment at June 17 public hearing on USTR plan for 25% tariff on imports from China not included in three earlier rounds of duties. NPA applauds USTR for allowing exclusion process for imported products valued at $200bn already hit with tariffs in 2018.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel